Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone

PURPOSE: EndoPredict (EPclin) is a prognostic test validated to inform decisions on adjuvant chemotherapy to endocrine therapy alone for patients with oestrogen receptor-positive, HER2-negative breast cancer. Here, we determine the performance of EPclin for estimating 10-year distant recurrence-free...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Breast Cancer Res Treat
Glavni autori: Sestak, Ivana, Martín, Miguel, Dubsky, Peter, Kronenwett, Ralf, Rojo, Federico, Cuzick, Jack, Filipits, Martin, Ruiz, Amparo, Gradishar, William, Soliman, Hatem, Schwartzberg, Lee, Buus, Richard, Hlauschek, Dominik, Rodríguez-Lescure, Alvaro, Gnant, Michael
Format: Artigo
Jezik:Inglês
Izdano: Springer US 2019
Teme:
Clinical Trial
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6555778/
https://ncbi.nlm.nih.gov/pubmed/31041683
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-019-05226-8
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items